Abstract 14941: Efficacy and Safety of Factor XIa Inhibitors for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Wirksamkeit und Sicherheit von Faktor-XIa-Inhibitoren zur sekundären Prävention des nicht kardioembolischen ischämischen Schlaganfalls: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.14941 ↗Auf einen Blick
Drei RCTs mit 16.501 Patient:innen zeigen: Faktor-XIa-Inhibitoren senkten das Risiko für einen rezidivierenden ischämischen Schlaganfall gegenüber Placebo. Für Blutungsendpunkte zeigte sich kein signifikanter Unterschied.
Fragestellung
Sind Faktor-XIa-Inhibitoren wirksam und sicher zur sekundären Prävention bei nicht kardioembolischem ischämischem Schlaganfall?
Methode
Systematische Suche in PubMed, Cochrane, Scopus und EMBASE bis 8. Mai 2026; eingeschlossen wurden RCTs mit Faktor-XIa-Inhibitoren vs. Placebo bei NCIS oder Hochrisiko-TIA. Random-effects-Analyse.
Ergebnisse
Rezedivierender ischämischer Schlaganfall: RR 0,77 (95 %-KI 0,68–0,86; I2 = 0%). Gesamtmortalität: RR 1,00 (95 %-KI 0,85–1,18). Major Bleeding: RR 1,13 (95 %-KI 0,89–1,45); CRNM: RR 1,54 (95 %-KI 0,89–2,66); ICH: RR 1,11 (95 %-KI 0,73–1,70).
Schlussfolgerung der Autor:innen
Faktor-XIa-Inhibitoren senken laut Autor:innen das Risiko für rezidivierenden ischämischen Schlaganfall bei NCIS. Gegenüber Placebo zeigte sich kein erhöhtes Risiko für Major Bleeding, CRNM oder ICH.
Kernaussagen
- RR 0,77 (95 %-KI 0,68–0,86) für rezidivierenden ischämischen Schlaganfall
- Keine signifikante Differenz bei Major Bleeding, CRNM und ICH
- 3 RCTs mit 16.501 Patient:innen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Arooba Ejaz und 4 weiteren Autor:innen.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Despite guideline-recommended antiplatelet therapy, recurrent stroke risk remains high following noncardioembolic ischemic stroke (NCIS). Factor XIa inhibitors, including asundexian and milvexian, selectively target pathological thrombosis while preserving hemostasis, representing a novel antithrombotic strategy. This meta-analysis aims to assess the efficacy and safety of Factor XIa inhibitors for secondary prevention of NCIS.
Methods
Following PRISMA guidelines, a systematic search was conducted in PubMed, Cochrane, Scopus, and EMBASE databases up to May 8, 2026. Randomized controlled trials (RCTs) were included, comparing Factor XIa inhibitors with placebo in patients with NCIS or high-risk transient ischemic attack. The primary outcome was the incidence of recurrent ischemic stroke, and secondary efficacy and safety outcomes included all-cause mortality, major bleeding, clinically relevant non-major bleeding (CRNM), and intracranial hemorrhage (ICH). Data were extracted and analyzed using random-effects models to calculate risk ratios (RR) and 95% confidence intervals (CI).
Results
Three RCTS (N=16501) were included. The pooled analysis showed that Factor XIa inhibitors significantly reduced the risk of recurrent ischemic stroke than placebo (RR 0.77, 95% CI 0.68-0.86, P < 0.00001; I 2 = 0%). The use of Factor XIa inhibitors did not significantly reduce all-cause mortality (RR 1.00, 95% CI 0.85-1.18, P = 0.98, I 2 = 0%). For safety outcomes, there was no significant difference between the two groups for major bleeding (RR 1.13, 95% CI 0.89-1.45, P = 0.32; I 2 = 0%), CRNM (RR 1.54, 95% CI 0.89-2.66, P = 0.12, I 2 = 62%), and ICH (RR 1.11, 95% CI 0.73-1.70, P = 0.62; I 2 = 0%).
Conclusion
In conclusion, Factor XIa inhibitors significantly reduce the risk of recurrent ischemic stroke in patients with NCIS. No increased risk of major bleeding, CRNM, and ICH was seen with Factor XIa inhibitors compared with placebo. These findings suggest that Factor XIa inhibitors are a promising class of drugs for secondary stroke prevention in patients with NCIS and also have a stable hemostatic profile.
Zitieren
APA
Ejaz, A., Hashmi, S. M. F., Khan, N., Ejaz, A., & Ahmed, A. (2026). Abstract 14941: Efficacy and Safety of Factor XIa Inhibitors for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.14941
Vancouver
Ejaz A, Hashmi SMF, Khan N, Ejaz A, Ahmed A. Abstract 14941: Efficacy and Safety of Factor XIa Inhibitors for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.14941
BibTeX
@article{Ejaz2026,
author = {Ejaz, Arooba and Hashmi, Syed Muhammad Fuzail and Khan, Naima and Ejaz, Aneeqa and Ahmed, Aymen},
title = {Abstract 14941: Efficacy and Safety of Factor XIa Inhibitors for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.14941}
}
EUVIMED